Optimization of tactics of management of patients with chronic hepatitis C

Abstract

The prognostic significance of characteristics of patients (gender, age, infectious dose, the presence of habitual intoxication) and of the virus (replicative activity, genotype, viral load, viral kinetics) in the natural course of HCV infection and the probability of achieving sustained virologic response (SVR) as a result of antiviral therapy (AVT ) were studied. The natural course of chronic hepatitis C (CHC) infection in 100 patients and the effectiveness of AVT in 68 CHC patients have been analyzed. The factors that determine the unfavorable course of CHC (male gender, age at the moment of infection older than 30 years, infection through a hemotransfusion or drug use, the presence of habitual intoxications, virus 3a genotype, and the presence of a/HCV NS3 and a/HCV NS5). The factors that determine a high probability of achieving SVR are detected. In this case the treatment by AVT, regardless of the prognosis of the natural course of HCV is recommended

Keywords

hepatitis C / predictors of progression / tactics of the management

References

[1] Alter H. J., Seeff L. B. Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin. Liver Dis. 2000; 20(1): 17-35.

[2] Bochud P.Y., Cai T., Overbeck K. et al. Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. J. Hepatol. 2009; 51 (4): 655-66.

[3] Poynard T., Bedossa P., Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet. 1997; 349: 825-832.

[4] Wiese M., Berr F., Lafrenz M. et al. Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in germany: a 20-year multicenter study. Hepatology. 2000; 32: 91-6.

[5] Di Martino V., Lebray P., Myers R. P. et al. Progression of liver fibrosis in women infected with hepatitis C: long-term benefit of estrogen exposure. Hepatology. 2004; 40: 1426-33.

[6] Fontaine H., Nalpas B., Poulet B. et al. Hepatitis activity index is a key factor in determining the natural history of chronic hepatitis C. Hum. Pathol. 2001; 32: 904-9.

[7] Friedman S. L. Liver fibrosis - from bench to bedside. J. Hepatol. 2003; 38: 38-53.

[8] Ghany M. G., Kleiner D. E., Alter H. et al. Progression of fibrosis in chronic hepatitis C. Gastroenterology. 2003; 124: 97-104.

[9] Minola E., Prati D., Suter F. et al. Age at infection affects the long-term outcome of transfusion-associated chronic hepatitis C. Blood. 2002; 99: 4588-91.

[10] Ryder S. D., Irving W. L., Jones D. A. et al. Progression of hepatic fibrosis in patients with hepatitis C: a prospective repeat liver biopsy study. Gut. 2004; 53: 451-5.

[11] Thabut D., Le Calvez S., Thibault V. et al. Hepatitis C in 6,865 Patients 65 yr or Older: A Severe and Neglected Curable Disease? Am. J. Gastroenterology. 2006; 101: 1260-67.

[12] Harris D. R., Gonin R., Alter H. J. et al. The relationship of acute transfusion-associated hepatitis to the development of cirrhosis in the presence of alcohol abuse. Ann. Intern. Med. 2001; 134: 120-4.

[13] Berg T., Sarrazin C., Herrmann E. et al. Prediction of Treatment Outcome in Patients With Chronic Hepatitis C: Significance of Baseline Parameters and Viral Dynamics During Therapy. Hepatology. 2003; 37 (3): 600-9.

[14] Marcellin P., Reau N., Ferenci P. et al. Refined prediction of week 12 response and SVR based on week 4 response in HCV genotype 1 patients treated with peginterferon alfa-2a (40KD) and ribavirin. J. Hepatol. 2012; 56(6): 1276-82.

RIGHTS & PERMISSIONS

Eco-vector